

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 01-01-2024)						
State of Nevada - Actual and Estimated Allocations to the Fund for a Resilient Nevada						
(assumes no default in payments)						
(CMS Medicaid costs, if any, not deducted)						
(assumes no administrative fees for court appointed third-party administrators)						
Settlement/Bankruptcy (BK)	Estimated/Actual Recovery Year	Estimated/Actual Recovery Month	Total Recovery Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation After Fees
McKinsey	2021	September	\$ 28,461,750.49	\$ 5,407,732.59	\$ -	\$ 23,054,017.90
Janssen - J&J	2022	April	\$ 18,612,345.20	\$ 3,536,345.59	\$ -	\$ 15,075,999.61
Distributors	2022	August	\$ 4,340,895.22	\$ 824,770.09	\$ -	\$ 3,516,125.13
Distributors	2022	September	\$ 4,562,069.29	\$ 866,793.17	\$ -	\$ 3,695,276.12
American Drug Stores	2022	November	\$ 657,900.01	\$ 131,580.00	\$ -	\$ 526,320.01
Mallinckrodt (BK)	2022	November	\$ 811,293.19	\$ 162,258.64	\$ -	\$ 649,034.55
Mallinckrodt (BK)	2022	November	\$ 17.58	\$ -	\$ -	\$ 17.58
Distributors	2023	July	\$ 4,562,069.29	\$ 866,793.17	\$ -	\$ 3,695,276.12
Allergan	2023	July	\$ 1,660,972.77	\$ 123,850.76	\$ 1,458,406.49	\$ 1,537,122.01
CVS	2023	August	\$ 6,877,247.99	\$ -	\$ 5,731,040.01	\$ 6,877,247.99
Mallinckrodt (BK)	2023	October	\$ -	\$ (162,258.64)	\$ -	\$ 162,258.64
Mallinckrodt (BK)	2023	December	\$ 954,483.23	\$ -	\$ -	\$ 954,483.23
Walgreens	2023	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Janssen - J&J (Fee Fund)	2024	January	\$ -	\$ (4,603,844.83)	\$ -	\$ 4,603,844.83
Distributors (Fee Fund)	2024	January	\$ -	\$ (15,432,662.80)	\$ -	\$ 15,432,662.80
Janssen - J&J (Fee Fund)	2024	January	\$ -	\$ (302,274.46)	\$ -	\$ 302,274.46
Distributors (Fee Fund)	2024	January	\$ -	\$ (1,302,503.98)	\$ -	\$ 1,302,503.98
Distributors (Fee Fund)	2024	January	\$ -	\$ (589,362.17)	\$ -	\$ 589,362.17
Janssen - J&J (Fee Fund)	2024	January	\$ -	\$ (90.30)	\$ -	\$ 90.30
Masters	2024	February	\$ 626,563.03	\$ 134,711.05	\$ -	\$ 491,851.98
Walmart	2024	February	\$ 5,371,882.50	\$ -	\$ 1,511,506.58	\$ 5,371,882.50
Walmart	2024	March	\$ 8,340,554.42	\$ -	\$ -	\$ 8,340,554.42
Purdue (BK)	2024	July	\$ 24,561,600.00	\$ 5,280,744.00	\$ -	\$ 19,280,856.00
Distributors	2024	July	\$ 5,710,075.94	\$ 1,084,914.43	\$ -	\$ 4,625,161.51
Janssen - J&J (Fee Fund)	2024	January	\$ -	\$ (302,274.46)	\$ -	\$ 302,274.46
Allergan	2024	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2024	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
CVS	2024	August	\$ 6,877,247.99	\$ -	\$ 5,731,040.01	\$ 6,877,247.99
Walgreens	2024	December	\$ 6,541,719.00	\$ -	\$ 6,718,803.74	\$ 6,541,719.00
Walmart	2025	February	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Janssen - J&J	2025	April	\$ 1,173,447.81	\$ 272,955.08	\$ -	\$ 900,492.73
Distributors	2025	July	\$ 5,710,075.94	\$ 1,084,914.43	\$ -	\$ 4,625,161.51
Allergan	2025	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2025	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
CVS	2025	August	\$ 6,877,247.99	\$ -	\$ 5,731,040.01	\$ 6,877,247.99
Walgreens	2025	December	\$ 6,541,719.00	\$ -	\$ 6,718,803.74	\$ 6,541,719.00
Walmart	2026	February	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Distributors	2026	July	\$ 5,710,075.94	\$ 1,084,914.43	\$ -	\$ 4,625,161.51
Allergan	2026	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2026	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
CVS	2026	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2026	December	\$ 6,541,719.00	\$ -	\$ 6,718,803.74	\$ 6,541,719.00
Walmart	2027	February	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Distributors	2027	July	\$ 5,710,075.94	\$ 1,084,914.43	\$ -	\$ 4,625,161.51
Allergan	2027	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2027	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2027	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2027	December	\$ 6,541,719.00	\$ -	\$ 6,718,803.75	\$ 6,541,719.00
Walmart	2028	February	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Distributors	2028	July	\$ 6,715,737.27	\$ 1,275,990.08	\$ -	\$ 5,439,747.19
Allergan	2028	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2028	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2028	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2028	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2029	July	\$ 6,715,737.27	\$ 1,275,990.08	\$ -	\$ 5,439,747.19
Allergan	2029	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2029	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2029	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2029	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2030	July	\$ 6,715,737.27	\$ 1,275,990.08	\$ -	\$ 5,439,747.19
Teva	2030	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2030	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2030	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2031	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2031	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2031	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2031	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2032	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2032	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2032	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2032	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2033	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2033	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
Walgreens	2033	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2034	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2034	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
Walgreens	2034	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2035	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2035	July	\$ 3,137,299.64	\$ -	\$ -	\$ 3,137,299.64
Walgreens	2035	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2036	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2036	July	\$ 3,137,299.64	\$ -	\$ -	\$ 3,137,299.64
Walgreens	2036	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2037	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2037	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Walgreens	2037	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2038	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2038	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2039	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2040	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2041	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2042	July	\$ 12,101,012.85	\$ -	\$ -	\$ 12,101,012.85
Teva	2043	July	\$ 12,101,012.85	\$ -	\$ -	\$ 12,101,012.85
Subtotals			\$ 435,552,786.64	\$ 12,354,782.54	\$ 64,955,058.06	\$ 423,198,004.10
Totals			\$ 435,552,786.64	\$ 77,309,840.60	\$ 423,198,004.10	
			Recoveries	Attorney Fees	Net Allocation	